

**Extraordinary Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization  
8 February 2021  
Virtual meeting  
Final agenda**

**Monday, 8 February 2021**

| <b>Time</b>  | <b>Session</b>  | <b>Purpose of session, target outcomes and questions for SAGE</b>  | <b>Duration</b> |
|--------------|---|--|-----------------|
| 11:00        | <b>Closed SAGE meeting</b>  | Preparation of the session.  | 30 min.         |
| <b>11:30</b> | <b>Break</b>  | <b>Break</b>   | <b>30 min.</b>  |
| 12:00        | <b>Opening and welcome</b><br><br>Welcome: A. Cravioto. SAGE Chair. 5 min.  | <b>Opening of the Plenary Meeting</b>  | 5 min.          |
| 12:05        | <b>COVID-19 vaccine - part 1</b><br><br>Update on recent developments including on COVAX. K. O'BRIEN. Director Immunization Vaccines and Biologicals (IVB). 10 min.<br><br>Introduction and objective setting. H. NOHYNEK. SAGE Member. 5 min.<br><br>Vaccine safety and efficacy data emerging on AstraZeneca's COVID-19 vaccine, also known as AZD1222, clinical trials (phase 1-3 trial results). Risk management plans and other implementation considerations. COMPANY PRESENTATION. 25 min.<br><br>Questions. 15 min. | <b>FOR RECOMMENDATION</b><br><br>Purpose: Update on vaccine registration, vaccine introduction status and COVAX.<br><br>Presentation of clinical data on AZD1222 vaccine from phase 1, 2 and 3 studies on safety, immunogenicity and efficacy. Outline of ongoing and planned studies.   | 55 min.         |
| <b>13:00</b> | <b>Break</b>  | <b>Break</b>   | <b>10 min.</b>  |
| 13:10        | <b>COVID-19 vaccine – part 2</b><br><br>Assessment of the critical evidence, including data and draft recommendations related to vaccine use in older adults. SAGE working group. 30 min.<br><br>Discussion. 30 min.<br><br>Emerging data on the use of AZD1222 in the context of new virus variants. A. POLLARD and S. MADHI. SAGE Members. 15 min.<br><br>Discussion. 15 min.<br><br>Presentation of the remaining draft recommendations. H. NOHYNEK. SAGE Member. 20 min.<br><br>Discussion. 30 min.                     | <b>FOR RECOMMENDATION</b><br><br>Presentation of the assessment of the SAGE working group on the available evidences and the strength of evidences on the questions of the evidence to decision tables. Specific focus is given to the discussion on vaccine use in older adults.<br><br>Presentation on recently emerged data around vaccine use in the context of virus variants.<br><br>Based on the presented evidences, presentation of draft recommendations on the use of AZD1222 vaccine against COVID-19. | 2h 20 min.      |
| <b>15:30</b> | <b>End of the meeting</b>   |  |                 |